NCT00138762已完成3 期
A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 3,800
- 试验地点
- 151
- 主要终点
- LDL and HDL levels
研究概览
简要总结
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
详细描述
For additional information please call: 1-800-718-1021
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •subjects with elevated cholesterol
排除标准
- •Women who are pregnant or lactating, or planning to become pregnant.
- •Intolerance to statin therapy resulting in withdrawal
- •Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- •Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
结局指标
主要结局
LDL and HDL levels
次要结局
- other lipid parameters
研究者
研究点 (151)
Loading locations...
相似试验
终止
3 期
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart DiseaseCoronary DiseaseDiabetes MellitusNCT00134264Pfizer15,067
已完成
3 期
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.HyperlipidemiaNCT00137462Pfizer900
已完成
3 期
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial HypercholerolemiaHypercholesterolemia, FamilialHyperlipidemiaNCT00134485Pfizer400
终止
3 期
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.Hyperlipoproteinemia Type IIINCT00145431Pfizer41
已完成
3 期
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart DiseaseCoronary DiseaseCoronary ArteriosclerosisHyperlipidemiaNCT00134173Pfizer1,100